title: Comparison of the effects of fentanyl, remifentanil, and dexmedetomidine on neuromuscular blockade.
abstract: OBJECTIVE
  The aim of our study was to compare the effects of fentanyl, remifentanil, and dexmedetomidine on neuromuscular blockade under sevoflurane anesthesia.
  
  
  METHODS
  Eighty-four patients were randomized to fentanyl, remifentanil, and dexmedetomidine groups. In the fentanyl group, fentanyl 1.5 μg/kg was given before induction of anesthesia, and additional 50-μg boluses were administered. In the remifentanil group, the initial dose of remifentanil 1 μg/kg was infused in 10 min before induction and 0.1 μg/kg/min infusion was continued during anesthesia. In the dexmedetomidine group, the initial dose of dexmedetomidine 1 μg/kg was infused in 10 min before induction and 1 μg/kg/h infusion was continued during anesthesia. Heart rate, blood pressure, SpO(2), EtCO(2), and TOF (train-of-four) values of all patients were monitored during anesthesia. Times to reach TOF 0 and TOF 25% and intubation quality were recorded.
  
  
  RESULTS
  T                            (0) times and quality of intubation were found to be similar among the groups. T                            (25) time was found to be significantly longer in the dexmedetomidine group than in the fentanyl and remifentanil groups.
  
  
  CONCLUSIONS
  Dexmedetomidine infusion increased the duration of neuromuscular blockade with vecuronium during general anesthesia. In addition to analgesic and sedative effects, dexmedetomidine may enhance the duration of neuromuscular blockade and may be used as an adjuvant anesthetic during general anesthesia.
authors: Department of Anesthesiology and Reanimation, Ankara Training and Research Hospital, Ankara, Turkey. ayseongun@gmail.com
authors: Ayse
authors: A
authors: Ozcan
authors: Namik
authors: N
authors: Ozcan
authors: Handan
authors: H
authors: Gulec
authors: Fatma
authors: F
authors: Yalcin
authors: Hulya
authors: H
authors: Basar
mesh_terms: D000759:Adjuvants, Anesthesia / Q000008:administration & dosage*; D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage; D000328:Adult; D018685:Anesthetics, Inhalation / Q000008:administration & dosage; D018686:Anesthetics, Intravenous / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D020927:Dexmedetomidine / Q000008:administration & dosage*; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage*; D008297:Male; D008738:Methyl Ethers / Q000008:administration & dosage; D019148:Neuromuscular Blockade / Q000379:methods*; D018733:Nicotinic Antagonists / Q000008:administration & dosage; D010880:Piperidines / Q000008:administration & dosage*; D000077208:Remifentanil; D000077149:Sevoflurane; D014673:Vecuronium Bromide / Q000008:administration & dosage
chemical_list: D000759:Adjuvants, Anesthesia; D058647:Adrenergic alpha-2 Receptor Agonists; D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D006993:Hypnotics and Sedatives; D008738:Methyl Ethers; D018733:Nicotinic Antagonists; D010880:Piperidines; D000077149:Sevoflurane; D020927:Dexmedetomidine; D014673:Vecuronium Bromide; D000077208:Remifentanil; D005283:Fentanyl